This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 0.00% and -49.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -25.00% and -61.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Pieris (PIRS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Pieris (PIRS) stock based on the movements in the options market lately.
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 58.82% and 141.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Pieris Pharmaceuticals (PIRS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gene Therapy the Next Best Thing: Here's Why (Revised)
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why
by Zacks Equity Research
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Pieris Pharmaceuticals (PIRS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.
Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 26.67% and 35.54%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals (PIRS) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -100.00% and -13.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Proteostasis Therapeutics (PTI) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Proteostasis Therapeutics (PTI) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) saw a big move last session, as its shares jumped more than 15% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?
by Zacks Equity Research
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.